Boditech Med Executive and Leadership Team

Yule Choi, the Chief Executive Officer at Boditech Med, directs the overarching corporate strategy and global market expansion efforts. By overseeing the commercial deployment of diagnostic solutions, the Chief Executive Officer ensures that the company maintains a competitive edge in the point-of-care testing sector. Yule Choi manages high-level relationships with international stakeholders to facilitate the distribution of 85 distinct biomarkers across diverse healthcare markets. This leadership role involves aligning internal operational goals with the evolving needs of clinicians in 120 countries. Through the optimization of resource allocation and the pursuit of sustainable growth, the Chief Executive Officer drives the organization toward long-term financial stability. By fostering a culture of excellence, the Chief Executive Officer strengthens the market position of the firm. Ultimately, the Chief Executive Officer secures the future of the company by prioritizing innovation and operational efficiency in every diagnostic product launch.

Euiyul Choi, the Founder & Chief Executive Officer at Boditech Med, architects the foundational vision and long-term mission for the organization. As the primary visionary, the Founder & Chief Executive Officer guides the development of in-vitro diagnostic solutions that improve patient quality of life. Euiyul Choi oversees the strategic integration of research initiatives with commercial objectives to ensure that the company remains a global leader in point-of-care testing. This leadership role requires constant engagement with the Board to refine the corporate trajectory and maintain the high standards established since the inception of the firm. By focusing on the expansion of the biomarker portfolio, the Founder & Chief Executive Officer ensures that the company addresses complex clinical requirements. Through the implementation of rigorous quality control measures, the Founder & Chief Executive Officer guarantees that every diagnostic tool meets international regulatory standards while supporting healthcare providers in diverse geographic regions.

Eui-Yul Choi, the Co-Founder & Chief Executive Officer at Boditech Med, executes the strategic roadmap for organizational growth and operational excellence. By focusing on the scalability of diagnostic platforms, the Co-Founder & Chief Executive Officer ensures that the company effectively serves the needs of clinicians in 120 countries. Eui-Yul Choi manages the alignment of internal departments to support the rapid deployment of new in-vitro diagnostic solutions. This leadership role involves identifying emerging market opportunities and directing the necessary investments to capture significant market share. Through the oversight of cross-functional teams, the Co-Founder & Chief Executive Officer maintains the integrity of the product pipeline and the efficiency of the supply chain. By prioritizing the development of capillary and venous blood testing technologies, the Co-Founder & Chief Executive Officer strengthens the reputation of the firm as a pioneer in point-of-care diagnostics. This commitment to innovation drives the company toward continued success.

Keith Nahm, the Chief Technology Officer at Boditech Med, directs the research and development of advanced diagnostic technologies and biomarker innovation. Overseeing the technical infrastructure, the Chief Technology Officer ensures that the company remains at the forefront of in-vitro diagnostic solutions. Keith Nahm manages the engineering teams responsible for creating high-precision testing tools that support capillary, venous, and plasma analysis. This leadership role involves collaborating with the executive team to translate scientific breakthroughs into scalable commercial products. By optimizing the R&D lifecycle, the Chief Technology Officer accelerates the time-to-market for new diagnostic biomarkers. Through the implementation of cutting-edge laboratory processes, the Chief Technology Officer enhances the accuracy and reliability of the entire product portfolio. By maintaining a focus on technological advancement, the Chief Technology Officer supports the global mission of the company to improve patient health outcomes through superior diagnostic performance and consistent innovation.